Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Assault: A Retrospective Real-World Study.

Authors :: Jesús, Cabrera-López Teresita de
Edgar, Pérez-Barragán
Ruben, Nava-Campos Carlos
Marla, Toiber-Rodríguez
Carlos, Rodríguez-Aldama Juan
Adrián, Cruz-Flores Raúl
Andrea, González-Rodríguez
Source :: Open Forum Infectious Diseases. Aug2024, Vol. 11 Issue 8, p1-3. 3p.
Publication Year :: 2024
Abstract: We report the experience of bictegravir/emtricitabine/tenofovir alafenamide for nonoccupational postexposure prophylaxis in sexual assault cases. Between June 2021 and October 2023, 39 individuals completed the 28-day follow-up; 41% experienced some side effects, and 1 person discontinued the drug because of a rash. No individuals seroconverted to HIV during the follow-up period. [ABSTRACT FROM AUTHOR]

Subjects :: *SEXUAL assault
*TENOFOVIR
*EMTRICITABINE
*HIV
*PREVENTIVE medicine

Full Text Access

Tools